Global Blood Therapeutics (Global Blood Therapeutics) Market Cap : $4,621.4 Mil (As of May. 25, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Global Blood Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Global Blood Therapeutics's share price for the quarter that ended in Jun. 2022 was $31.95. Global Blood Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2022 was 67.3 Mil. Therefore, Global Blood Therapeutics's market cap for the quarter that ended in Jun. 2022 was $2,149.4 Mil.

Global Blood Therapeutics's quarterly market cap increased from Dec. 2021 ($1,891.9 Mil) to Mar. 2022 ($2,253.5 Mil) but then declined from Mar. 2022 ($2,253.5 Mil) to Jun. 2022 ($2,149.4 Mil).

Global Blood Therapeutics's annual market cap declined from Dec. 2019 ($4,820.6 Mil) to Dec. 2020 ($2,680.8 Mil) and declined from Dec. 2020 ($2,680.8 Mil) to Dec. 2021 ($1,891.9 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Global Blood Therapeutics's Enterprise Value for Today is $4,762.7 Mil.

Global Blood Therapeutics Market Cap Historical Data

The historical data trend for Global Blood Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Blood Therapeutics Market Cap Chart

Global Blood Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Market Cap

Get a 7-Day Free Trial

1,815.28

2,284.03

4,820.62

2,680.81

1,891.91

Global Blood Therapeutics Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Market Cap	Get a 7-Day Free Trial															2,184.52	1,640.60	1,891.91	2,253.52	2,149.37

Competitive Comparison of Global Blood Therapeutics's Market Cap

For the Biotechnology subindustry, Global Blood Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Global Blood Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Global Blood Therapeutics's Market Cap falls into.

Global Blood Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Global Blood Therapeutics's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as

Market Cap (A: Dec. 2021 )	=	Share Price (A: Dec. 2021 )	*	Shares Outstanding (EOP) (A: Dec. 2021 )
	=	$29.27	*	64.6366
	=	$1,891.9

Global Blood Therapeutics's Market Cap for the quarter that ended in Jun. 2022 is calculated as

Market Cap (Q: Jun. 2022 )	=	Share Price (Q: Jun. 2022 )	*	Shares Outstanding (EOP) (Q: Jun. 2022 )
	=	$31.95	*	67.2728
	=	$2,149.4

Global Blood Therapeutics (NAS:GBT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Global Blood Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Global Blood Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Global Blood Therapeutics (Global Blood Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Global Blood Therapeutics Inc (NAS:GBT) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

181 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.gbt.com

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Executives

Jeffrey S Farrow	officer: Chief Financial Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Nazila Habibizad	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Philip A. Pizzo	director	ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Carrie Krehlik	officer: Chief Human Resources Officer	6015 COLTON BLVD, OAKLAND CA 94611
Eric Fink	officer: Chief Human Resources Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Kim Smith-whitley	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Alexis A. Thompson	director	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Brian Edwin Cathers	officer: Chief Scientific Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Lesley Ann Calhoun	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mark L Perry	director	176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
Ted W Love	director, officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Tricia Borga Suvari	officer: Chief Legal Officer	3172 PORTER DRIVE PALO ALTO CA 94034
Brown Willie L. Jr.	director	C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080